Valuation
- Market cap
- 1,000
- Revenue TTM
- $330,000
- Net income TTM
- $-37,990,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -11,512.12%
- Debt to equity
- 0.00
Trading
- Volume
- 100
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 8,220,000
- Stochastic %K
- —
- Beta
- 57.91
- Analysts
- —
- Price target
- —
Company profile
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer...
Show more
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 902 492 1819
- Address
- 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Canada
Latest news
No headlines yet.
